Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment

Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an update.

Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.

More about Keymed Biosciences, Inc.

Keymed Biosciences, Inc. is a company focused on the biotechnology industry, developing innovative therapeutic products. The company’s primary products include humanized antibodies targeting specific proteins involved in inflammatory processes, with a market focus on diseases such as atopic dermatitis and chronic rhinosinusitis.

YTD Price Performance: 2.43%

Average Trading Volume: 1,583,455

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$8.28B

For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.